Core Viewpoint - Unilever Plc has agreed to merge its food business with McCormick & Co. in a $44.8 billion deal, creating a global leader in seasonings, sauces, and condiments [1][2] Group 1: Deal Structure and Impact - McCormick will pay $15.7 billion in cash and $29.1 billion in shares for most of Unilever's food business, leaving Unilever with 65% ownership of the combined entity [1] - This merger is the largest in the histories of both companies, positioning Unilever as a leader in beauty and personal care while enhancing McCormick's competitiveness in the packaged food sector [2] Group 2: Market Reaction - Investor response to the merger has been negative, with McCormick's stock falling as much as 10% and Unilever's shares declining 7.3% in London, extending its year-to-date decline to nearly 14% [3][2] - Analysts have expressed skepticism about the rationale behind Unilever's decision to divest its food business, particularly given the strength of its brands like Hellmann's and Knorr [4] Group 3: Future Outlook - The combined company is expected to be highly leveraged, and the initial primary listing in New York may lead to selling pressure from European investors, affecting sentiment over the next 12 months [5] - Unilever has been facing challenges in the food sector due to changing consumer preferences and increased competition from cheaper store brands, with the CEO indicating a strategic shift towards beauty and personal care for future growth [6]

Core Viewpoint - The merger of Nichols Cauley, Partners Risk Services, and JGH Consulting aims to create a comprehensive platform that integrates accounting, insurance, and transaction advisory services for small and mid-sized businesses, entrepreneurs, and family-owned companies [1][6]. Group 1: Merger Details - Nichols Cauley is merging with Partners Risk Services and JGH Consulting to form a new platform [1]. - The merger is supported by Madison Dearborn Partners (MDP), which will provide growth investment and leverage its experience in financial services [2]. - The transaction is expected to close in the first quarter of 2026 [3]. Group 2: Leadership Structure - Todd Giddens, managing partner of Nichols Cauley, will become the chief operations officer of the new platform [2]. - Joe Thompson, CEO of Partners Risk Services, will lead risk management and insurance services, while Greg Hicks from JGH Consulting will oversee transaction advisory services [3]. - Alan Whitman is anticipated to serve as the CEO of the combined entity [3]. Group 3: Operational Changes - Post-merger, Nichols Cauley will operate under a new structure, with Nichols Cauley & Associates providing attest services and Nichols Cauley Advisory Group offering business advisory, tax, and other non-attest services [4]. Group 4: Strategic Intent - The merger is positioned as a strategy to enhance competitiveness and provide sophisticated business solutions to clients [5]. - The combined strengths of the firms are expected to amplify their ability to innovate and deliver value-added solutions across various service lines [6].

Financial Performance - Normalised revenue increased by 82.3% to $6.0085 billion[12, 21], and normalised EBIT increased by 41.4% to $834.5 million[11, 12, 21, 74] - Statutory NPAT increased by 40% to $579.1 million[12] - Pro-forma revenue reached $9.6 billion[13, 27], and pro-forma EBIT was $903.4 million[13, 27] - Net debt to normalised EBITDA ratio is 0.85x[14, 18, 37] Growth and Expansion - Chemist Warehouse (CW) retail network sales increased by 14% to $10.3 billion[10] - Australian CW franchise stores experienced 11.3% like-for-like sales growth[10, 30] - The company has expanded to 674 Chemist Warehouse stores globally[10, 46, 74] Synergies and Efficiencies - Synergies target upgraded to $100 million per annum by year four[10, 56, 58] - Distribution Centre (DC) volumes increased by 29% to over 532 million units[10, 57] - Logistics costs decreased by 11% per unit[10] Product Strategy - Over 20% growth in FY25 sales of own and exclusive label products[10, 54] - Launched Wagner generic medicines in November 2024[10, 54]

As filed with the Securities and Exchange Commission on October 5, 2023. Registration No. 333-272908 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549F AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________ SEQLL INC. (Exact name of registrant as specified in its charter) ___________________________ | Delaware | 3826 | 46-5319744 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Empl ...